Mediwound Net Worth
Mediwound Net Worth Breakdown | MDWD |
Mediwound Net Worth Analysis
Mediwound's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mediwound's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mediwound's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mediwound's net worth analysis. One common approach is to calculate Mediwound's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mediwound's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mediwound's net worth. This approach calculates the present value of Mediwound's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mediwound's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mediwound's net worth. This involves comparing Mediwound's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mediwound's net worth relative to its peers.
Enterprise Value |
|
To determine if Mediwound is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mediwound's net worth research are outlined below:
The company reported the previous year's revenue of 20.22 M. Net Loss for the year was (30.22 M) with profit before overhead, payroll, taxes, and interest of 2.77 M. | |
Mediwound currently holds about 10.41 M in cash with (13.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31. | |
Roughly 18.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from news.google.com: Is MediWound Ltd. a good long term investment - Overwhelming profit margins - jammulinksnews.com |
Mediwound uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mediwound. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mediwound's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of March 2024 Upcoming Quarterly Report | View | |
4th of June 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
21st of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Mediwound Target Price Consensus
Mediwound target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mediwound's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
6 | Strong Buy |
Most Mediwound analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mediwound stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mediwound, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMediwound Target Price Projection
Mediwound's current and average target prices are 21.00 and 30.00, respectively. The current price of Mediwound is the price at which Mediwound is currently trading. On the other hand, Mediwound's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Mediwound Target Price
Know Mediwound's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mediwound is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mediwound backward and forwards among themselves. Mediwound's institutional investor refers to the entity that pools money to purchase Mediwound's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | State Street Corp | 2025-03-31 | 72.1 K | Sargent Investment Group, Llc | 2025-03-31 | 68.7 K | Ubs Group Ag | 2025-03-31 | 67.8 K | Dafna Capital Management Llc | 2025-03-31 | 64.5 K | Vanguard Group Inc | 2025-03-31 | 61.5 K | Legato Capital Management Llc | 2025-03-31 | 43.2 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 36.6 K | Meitav Dash Investments Ltd | 2025-03-31 | 31.5 K | Charles Schwab Investment Management Inc | 2025-03-31 | 22.5 K | Investors Finance Co Plc | 2025-03-31 | 872.1 K | Yelin Lapidot Holdings Management Ltd | 2025-03-31 | 858 K |
Follow Mediwound's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 221.45 M.Market Cap |
|
Project Mediwound's profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.41) | (0.43) | |
Return On Capital Employed | (0.41) | (0.43) | |
Return On Assets | (0.41) | (0.43) | |
Return On Equity | (0.97) | (1.02) |
When accessing Mediwound's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mediwound's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mediwound's profitability and make more informed investment decisions.
Please note, the presentation of Mediwound's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mediwound's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mediwound's management manipulating its earnings.
Evaluate Mediwound's management efficiency
Mediwound has return on total asset (ROA) of (0.1988) % which means that it has lost $0.1988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7792) %, meaning that it created substantial loss on money invested by shareholders. Mediwound's management efficiency ratios could be used to measure how well Mediwound manages its routine affairs as well as how well it operates its assets and liabilities. As of July 24, 2025, Return On Tangible Assets is expected to decline to -0.43. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, Mediwound's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.29, whereas Non Currrent Assets Other are forecasted to decline to about 310.2 K.Last Reported | Projected for Next Year | ||
Book Value Per Share | 3.13 | 3.59 | |
Tangible Book Value Per Share | 3.12 | 3.28 | |
Enterprise Value Over EBITDA | (6.21) | (6.52) | |
Price Book Value Ratio | 5.69 | 6.09 | |
Enterprise Value Multiple | (6.21) | (6.52) | |
Price Fair Value | 5.69 | 6.09 | |
Enterprise Value | 174.6 M | 149 M |
Effective management at Mediwound has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Enterprise Value Revenue 9.8688 | Revenue | Quarterly Revenue Growth (0.20) | Revenue Per Share | Return On Equity |
Mediwound Corporate Filings
6K | 21st of May 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
12th of May 2025 Other Reports | ViewVerify | |
28th of March 2025 Other Reports | ViewVerify | |
13A | 23rd of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Mediwound Earnings Estimation Breakdown
The calculation of Mediwound's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Mediwound is estimated to be -0.492 with the future projection ranging from a low of -0.58 to a high of -0.3225. Please be aware that this consensus of annual earnings estimates for Mediwound is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.58 Lowest | Expected EPS | -0.32 Highest |
Mediwound Earnings Projection Consensus
Suppose the current estimates of Mediwound's value are higher than the current market price of the Mediwound stock. In this case, investors may conclude that Mediwound is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Mediwound's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
6 | 53.47% | 0.0 | -0.492 | -2.05 |
Mediwound Earnings per Share Projection vs Actual
Actual Earning per Share of Mediwound refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Mediwound predict the company's earnings will be in the future. The higher the earnings per share of Mediwound, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Mediwound Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Mediwound, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Mediwound should always be considered in relation to other companies to make a more educated investment decision.Mediwound Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Mediwound's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-27 | 2025-03-31 | -0.662 | -0.07 | 0.592 | 89 | ||
2025-03-19 | 2024-12-31 | -0.6075 | -0.36 | 0.2475 | 40 | ||
2024-11-19 | 2024-09-30 | -0.44 | -0.98 | -0.54 | 122 | ||
2024-08-14 | 2024-06-30 | -0.42 | -0.68 | -0.26 | 61 | ||
2024-05-29 | 2024-03-31 | -0.41 | -1.05 | -0.64 | 156 | ||
2024-03-21 | 2023-12-31 | -0.23 | -0.19 | 0.04 | 17 | ||
2023-11-21 | 2023-09-30 | -0.44 | -0.24 | 0.2 | 45 | ||
2023-08-15 | 2023-06-30 | -0.4 | 0.1 | 0.5 | 125 | ||
2023-05-30 | 2023-03-31 | -0.3 | -0.44 | -0.14 | 46 | ||
2023-03-16 | 2022-12-31 | -0.59 | -1.18 | -0.59 | 100 | ||
2022-11-09 | 2022-09-30 | -0.7 | -0.91 | -0.21 | 30 | ||
2022-08-09 | 2022-06-30 | -0.68 | -0.84 | -0.16 | 23 | ||
2022-05-17 | 2022-03-31 | -0.76 | -0.84 | -0.08 | 10 | ||
2022-03-17 | 2021-12-31 | -1.05 | -1.05 | 0.0 | 0 | ||
2021-11-16 | 2021-09-30 | -0.9 | -0.84 | 0.06 | 6 | ||
2021-08-10 | 2021-06-30 | -0.48 | -0.84 | -0.36 | 75 | ||
2021-05-05 | 2021-03-31 | -0.78 | -0.7 | 0.08 | 10 | ||
2021-02-25 | 2020-12-31 | -0.79 | -0.42 | 0.37 | 46 | ||
2020-11-10 | 2020-09-30 | -0.67 | -0.49 | 0.18 | 26 | ||
2020-08-06 | 2020-06-30 | -0.85 | -0.77 | 0.08 | 9 | ||
2020-05-20 | 2020-03-31 | -1 | -0.63 | 0.37 | 37 | ||
2020-02-25 | 2019-12-31 | -0.73 | -0.91 | -0.18 | 24 | ||
2019-11-14 | 2019-09-30 | -1.07 | -0.07 | 1.0 | 93 | ||
2019-08-13 | 2019-06-30 | -0.19 | 3.29 | 3.48 | 1831 | ||
2019-05-21 | 2019-03-31 | -0.97 | -1.05 | -0.08 | 8 | ||
2019-03-25 | 2018-12-31 | -1.06 | -0.35 | 0.71 | 66 | ||
2018-11-13 | 2018-09-30 | -1.37 | -0.77 | 0.6 | 43 | ||
2018-08-07 | 2018-06-30 | -1.38 | -1.05 | 0.33 | 23 | ||
2018-05-10 | 2018-03-31 | -1.1 | -1.19 | -0.09 | 8 | ||
2018-03-19 | 2017-12-31 | -1.19 | -0.63 | 0.56 | 47 | ||
2017-11-16 | 2017-09-30 | -1.33 | -3.43 | -2.1 | 157 | ||
2017-08-03 | 2017-06-30 | -1.37 | -1.4 | -0.03 | 2 | ||
2017-05-08 | 2017-03-31 | -1.18 | -1.4 | -0.22 | 18 | ||
2017-02-21 | 2016-12-31 | -1.74 | -0.63 | 1.11 | 63 | ||
2016-11-14 | 2016-09-30 | -1.8 | -1.82 | -0.02 | 1 | ||
2016-07-28 | 2016-06-30 | -1.63 | -2.38 | -0.75 | 46 | ||
2016-04-21 | 2016-03-31 | -1.69 | -1.96 | -0.27 | 15 | ||
2016-01-25 | 2015-12-31 | -1.63 | -2.52 | -0.89 | 54 | ||
2015-10-27 | 2015-09-30 | -2.16 | -1.19 | 0.97 | 44 | ||
2015-08-03 | 2015-06-30 | -1.85 | -1.33 | 0.52 | 28 | ||
2015-05-04 | 2015-03-31 | -1.76 | -2.1 | -0.34 | 19 | ||
2015-02-12 | 2014-12-31 | -1.79 | -2.31 | -0.52 | 29 | ||
2014-11-05 | 2014-09-30 | -1.65 | -1.68 | -0.03 | 1 | ||
2014-07-31 | 2014-06-30 | -1.22 | -1.96 | -0.74 | 60 | ||
2014-05-02 | 2014-03-31 | -1.17 | -0.35 | 0.82 | 70 |
Mediwound Corporate Management
Hagit Mashiach | VP Resources | Profile | |
CPA CPA | Ex Director | Profile | |
Hani Luxenburg | Chief Officer | Profile | |
Pr MD | CoFounder Director | Profile | |
Ety MBA | Chief Officer | Profile | |
Ofer BSc | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mediwound. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Mediwound Stock refer to our How to Trade Mediwound Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mediwound. If investors know Mediwound will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mediwound listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.05) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
The market value of Mediwound is measured differently than its book value, which is the value of Mediwound that is recorded on the company's balance sheet. Investors also form their own opinion of Mediwound's value that differs from its market value or its book value, called intrinsic value, which is Mediwound's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mediwound's market value can be influenced by many factors that don't directly affect Mediwound's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mediwound's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mediwound is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mediwound's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.